PT  - JOURNAL ARTICLE
AU  - Karin Hohloch
AU  - Angelika Bischof Delaloye
AU  - Christiane Windemuth-Kieselbach
AU  - Jose Gómez-Codina
AU  - Werner Linkesch
AU  - Woijciech Jurczak
AU  - Roberto Cacchione
AU  - Cheolwon Suh
AU  - Pier Luigi Zinzani
AU  - Lorenz Trümper
TI  - Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network
AID  - 10.2967/jnumed.111.089920
DP  - 2011 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1354--1360
VI  - 52
IP  - 9
4099  - http://jnm.snmjournals.org/content/52/9/1354.short
4100  - http://jnm.snmjournals.org/content/52/9/1354.full
SO  - J Nucl Med2011 Sep 01; 52
AB  - The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside randomized clinical studies. The RIT-N collects unbiased data on treatment indications, disease stages, patients’ conditions, lymphoma subtypes, and hematologic side effects of radioimmunotherapy treatment. Methods: RIT-N is located at the University of Göttingen, Germany, and collected data from 14 countries. Data were entered by investigators into a Web-based central database managed by an independent clinical research organization. Results: Patients (1,075) were enrolled from December 2006 until November 2009, and 467 patients with an observation time of at least 12 mo were included in the following analysis. Diagnoses were as follows: 58% follicular lymphoma and 42% other B-cell lymphomas. The mean overall survival was 28 mo for follicular lymphoma and 26 mo for other lymphoma subtypes. Hematotoxicity was mild for hemoglobin (World Health Organization grade II), with a median nadir of 10 g/dL, but severe (World Health Organization grade III) for platelets and leukocytes, with a median nadir of 7,000/μL and 2.2/μL, respectively. Conclusion: Clinical usage of radioimmunotherapy differs from the labeled indications and can be assessed by this registry, enabling analyses of outcome and toxicity data beyond clinical trials. This analysis proves that radioimmunotherapy in follicular lymphoma and other lymphoma subtypes is a safe and efficient treatment option.